Heparin should be administered to every patient admitted to the hospital with possible unstable angina.
作者信息
Brewster G S, Herbert M E
机构信息
Department of Emergency Medicine Olive View-UCLA Medical Center 14445 Olive View Dr, North Annex Sylmar, CA 91342, USA.
出版信息
West J Med. 2000 Aug;173(2):138-40. doi: 10.1136/ewjm.173.2.138.
Abstract
摘要
相似文献
1
Heparin should be administered to every patient admitted to the hospital with possible unstable angina.
West J Med. 2000 Aug;173(2):138-40. doi: 10.1136/ewjm.173.2.138.
2
Management of unstable angina and myocardial infarction.
Lancet. 2000 Sep 30;356(9236):1193-4. doi: 10.1016/s0140-6736(05)72890-7.
3
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
4
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
J Am Coll Cardiol. 1995 Aug;26(2):313-8. doi: 10.1016/0735-1097(95)80001-w.
5
[The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
Arq Bras Cardiol. 1995 Dec;65(6):517-8.
6
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
N Engl J Med. 1998 May 21;338(21):1488-97. doi: 10.1056/NEJM199805213382102.
7
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Ugeskr Laeger. 2010 Oct 18;172(42):2888-91.
8
Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
N Engl J Med. 1998 Jan 8;338(2):130; author reply 131.
9
Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
N Engl J Med. 1998 Jan 8;338(2):130-1.
10
[Antithrombotic therapy of unstable angina pectoris].
Duodecim. 1998;114(15):1441, 1443-4.
本文引用的文献
1
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J. 1999 Nov;20(21):1553-62. doi: 10.1053/euhj.1999.1879.
2
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Circulation. 1999 Oct 12;100(15):1593-601. doi: 10.1161/01.cir.100.15.1593.
3
4
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
Circulation. 1998 May 5;97(17):1702-7. doi: 10.1161/01.cir.97.17.1702.
5
Ardeparin and danaparoid for prevention of deep vein thrombosis.
Med Lett Drugs Ther. 1997 Oct 10;39(1011):94-5.
6
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
7
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Circulation. 1997 Jul 1;96(1):61-8. doi: 10.1161/01.cir.96.1.61.
8
Low-molecular-weight heparins for unstable angina. A better mousetrap?
Circulation. 1997 Jul 1;96(1):3-5.
9
10
Prediction of the need for intensive care in patients who come to emergency departments with acute chest pain.
N Engl J Med. 1996 Jun 6;334(23):1498-504. doi: 10.1056/NEJM199606063342303.
Zotero 插件